Bepotastine

Bepotastine

File:Bepotastine.png
Systematic (IUPAC) name
4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral, topical (eye drops)
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	High (oral) Minimal (topical)
Protein binding	~55%
Excretion	Renal (75–90%)
Identifiers
CAS Number	125602-71-3
ATC code	none
PubChem	CID 2350
DrugBank	DB04890
ChemSpider	2260
Chemical data
Formula	C21H25ClN2O3
Molar mass	388.88 g/mol[[]]

Bepotastine (Talion) is an antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the US rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.

ja:ベポタスチン